Inhibition of virus entry: an antiviral mechanism of emerging prominence.
Koszalka
George W
GW
Meanwell
Nicholas A
NA
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D065100:CCR5 Receptor Antagonists; D002448:Cell Adhesion; D015195:Drug Design; D000077560:Enfuvirtide; D006678:HIV / Q000187:drug effects* / Q000502:physiology; D015699:HIV Envelope Protein gp120 / Q000502:physiology; D015700:HIV Envelope Protein gp41 / Q000494:pharmacology / Q000627:therapeutic use; D023581:HIV Fusion Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D008561:Membrane Fusion; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use
D000998:Antiviral Agents; C477855:BMS-378806; D065100:CCR5 Receptor Antagonists; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D010879:Piperazines; D000077560:Enfuvirtide